OncoMatch/Clinical Trials/NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Is NCT05602363 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Docirbrutinib for b-cell malignancy.
Treatment: Docirbrutinib — This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: docirbrutinib (docirbrutinib)
Prior treatment with docirbrutinib
Cannot have received: noncovalent BTK inhibitor
Exception: pirtobrutinib (Jaypirca) allowed in Dose Expansion Cohort 3
Dose Escalation and Cohort 3 patients: prior treatment with noncovalent BTKi except pirtobrutinib (Jaypirca); Dose Expansion Cohort 1 and Cohort 2 patients: prior treatment with any noncovalent BTKi
Lab requirements
Blood counts
absolute neutrophil count ≥0.75 × 10⁹/L, platelet count ≥50 × 10⁹/L, hemoglobin ≥8 g/dL not requiring transfusion support or growth factors
Kidney function
Adequate renal function
Liver function
Adequate hepatic function
Cardiac function
No clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months before planned start of docirbrutinib, or prolongation of the QT interval corrected for heart rate using Fridericia's Formula (QTcF) >470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF >470 msec on all 3 ECGs, during Screening
Adequate hematologic status (ie, absolute neutrophil count ≥0.75 × 10⁹/L, platelet count ≥50 × 10⁹/L, hemoglobin ≥8 g/dL) not requiring transfusion support or growth factors; Adequate hepatic function; Adequate renal function; ... history of myocardial infarction within 6 months ... or prolongation of the QT interval ... QTcF >470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine Health · Orange, California
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- Moffitt Cancer Center · Tampa, Florida
- Northwestern Memorial Hospital · Chicago, Illinois
- American Oncology Partners · Fort Wayne, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify